Avenue Therapeutics (ATXI) Tops Q3 EPS by 34c

Avenue Therapeutics (NASDAQ: ATXI) reported Q3 EPS of $0.06, $0.34 better than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• US Tiger Securities Reiterates Hold Rating on Pinduoduo Inc. (PDD)
• X Financial (XYF) Tops Q2 EPS by 438c